OM:2CUREX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

2cureX AB (publ) operates as a medtech company in Europe. More Details


Snowflake Analysis

Flawless balance sheet with weak fundamentals.

Share Price & News

How has 2cureX's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 2CUREX's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-9.4%

2CUREX

-4.8%

SE Medical Equipment

-4.6%

SE Market


1 Year Return

9.5%

2CUREX

12.3%

SE Medical Equipment

9.8%

SE Market

Return vs Industry: 2CUREX underperformed the Swedish Medical Equipment industry which returned 11.7% over the past year.

Return vs Market: 2CUREX matched the Swedish Market which returned 9.5% over the past year.


Shareholder returns

2CUREXIndustryMarket
7 Day-9.4%-4.8%-4.6%
30 Day-16.8%-3.8%-1.3%
90 Day-25.2%-0.1%2.3%
1 Year9.5%9.5%14.0%12.3%11.7%9.8%
3 Yearn/a60.6%41.9%26.1%12.6%
5 Yearn/a65.0%36.8%52.1%22.6%

Price Volatility Vs. Market

How volatile is 2cureX's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is 2cureX undervalued compared to its fair value and its price relative to the market?

7.33x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 2CUREX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 2CUREX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 2CUREX is unprofitable, so we can't compare its PE Ratio to the SE Medical Equipment industry average.

PE vs Market: 2CUREX is unprofitable, so we can't compare its PE Ratio to the Swedish market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 2CUREX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 2CUREX is overvalued based on its PB Ratio (7.3x) compared to the SE Medical Equipment industry average (4.4x).


Next Steps

Future Growth

How is 2cureX forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

20.4%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as 2cureX has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has 2cureX performed over the past 5 years?

-27.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 2CUREX is currently unprofitable.

Growing Profit Margin: 2CUREX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 2CUREX is unprofitable, and losses have increased over the past 5 years at a rate of 27.4% per year.

Accelerating Growth: Unable to compare 2CUREX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2CUREX is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (18.4%).


Return on Equity

High ROE: 2CUREX has a negative Return on Equity (-31.83%), as it is currently unprofitable.


Next Steps

Financial Health

How is 2cureX's financial position?


Financial Position Analysis

Short Term Liabilities: 2CUREX's short term assets (SEK33.5M) exceed its short term liabilities (SEK10.0M).

Long Term Liabilities: 2CUREX has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: 2CUREX is debt free.

Reducing Debt: 2CUREX has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 2CUREX has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: 2CUREX has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 61.4% each year


Next Steps

Dividend

What is 2cureX current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 2CUREX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 2CUREX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 2CUREX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 2CUREX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 2CUREX's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Ole Thastrup (67 yo)

no data

Tenure

kr1,609,000

Compensation

Mr. Ole Thastrup, VD Co-founded 2cureX AB in 2006 and serves as its Chief Executive Officer, Chairman and Member of Executive Board. Prior to 2cureX, Mr. Thastrup served as Head of Carlsberg Biosector and ...


CEO Compensation Analysis

Compensation vs Market: Ole's total compensation ($USD185.09K) is about average for companies of similar size in the Swedish market ($USD231.20K).

Compensation vs Earnings: Ole's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Ole Thastrup
Co-Founderno datakr1.61m30.42%
SEK 54.4m
Grith Hagel
Co-Founder & Head of Project Managementno datano data4.99%
SEK 8.9m
Carit Andersen
Chief Financial Officer1.75yrsno data0.094%
SEK 168.7k
Henrik Harling
Chief Medical Officer1.33yrsno data0.19%
SEK 337.4k
Maarten van der Linden
Chief Business Officer2.75yrsno data0.060%
SEK 107.5k
Jürgen Kupper
Managing Director of GMBHno datano datano data

1.8yrs

Average Tenure

58.5yo

Average Age

Experienced Management: 2CUREX's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Ole Thastrup
Co-Founderno datakr1.61m30.42%
SEK 54.4m
Jørgen Drejer
Independent Director3.75yrskr100.00k0.10%
SEK 184.6k
Nils Brünner
Independent Director & Member of Clinical Advisory Boardno datano datano data
Povl-Andre Bendz
Independent Chairman of the Board3.75yrskr200.00k0.41%
SEK 738.5k
Michael Lutz
Independent Director0.25yrno datano data
Andreas Block
Member of Clinical Advisory Boardno datano datano data
Dion Morton
Member of Clinical Advisory Boardno datano datano data
Camilla Bondesson
Independent Director1.5yrskr100.00k0.27%
SEK 482.0k

3.8yrs

Average Tenure

65yo

Average Age

Experienced Board: 2CUREX's board of directors are considered experienced (3.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

2cureX AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: 2cureX AB (publ)
  • Ticker: 2CUREX
  • Exchange: OM
  • Founded: 2006
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: kr178.848m
  • Shares outstanding: 12.42m
  • Website: https://www.2curex.com

Number of Employees


Location

  • 2cureX AB (publ)
  • 2cureX
  • Fruebjergvej 3
  • Copenhagen
  • Capital Region of Denmark
  • 2100
  • Denmark

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
2CUREXOM (OMX Nordic Exchange Stockholm)YesShare CapitalSESEKNov 2017
2QEDB (Deutsche Boerse AG)YesShare CapitalDEEURNov 2017

Biography

2cureX AB (publ) operates as a medtech company in Europe. Its principal product is IndiTreat test that allows the physician to identify a medical treatment that is effective for a particular cancer patient ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/27 22:09
End of Day Share Price2020/10/27 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.